BTIG reiterates Buy rating on ORIC Pharmaceuticals, $26 price target

BTIG maintained a Buy rating on ORIC Pharmaceuticals with a $26 price target, suggesting a 188.9% upside from its Oct 27 close of $9. The firm cited strong early efficacy data for rinzimetostat and an attractive entry point ahead of the MEVPRO-1 readout.

Original reporting
Published Oct 28, 2026, 9:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BTIG reiterates Buy rating on ORIC Pharmaceuticals, $26 price target — source image
Decision brief

The 30-second read

$ORICBullishLow
01

Why it matters

The reiteration of a Buy rating with a substantially higher target may attract short-term buying interest.

02

Market read

Analyst upgrade provides a fresh catalyst for ORIC, potentially driving short-term price appreciation.

03

What to watch

Potential regulatory hurdles and competition in the mCRPC space could temper upside.

Relevance 4/10Novelty 2/10Timing: pre-market today

Background

BTIG's analyst note highlights early efficacy data for ORIC's rinzimetostat and sets a new price target.

Company-level read

Ticker impact

$ORICBullishMedium confidence
Context

BTIG reiterated a Buy rating on ORIC Pharmaceuticals with a new $26 price target, implying a 188.9% upside.

Expected impact

likely upward pressure as the market absorbs the higher target

Evidence & confidence

The rating change is new to the market and provides a concrete upside thesis, but no new operational data accompanies it.

Market effects

May boost sentiment in the biotech/oncology sector as peers see a higher valuation benchmark.

Limited to US biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

The price target may be overly optimistic given the early-stage data; investors could wait for more mature trial results.

Key entities

  • ORIC Pharmaceuticals

    Biotech firm developing oncology therapies.

  • BTIG

    Equity research firm issuing the rating.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo